fda glp-1 warning letters september 2025 news Patients taking an experimental oral drug lost significant weight and improved heart and metabolic risk factors in a large, worldwide phase 3 clinical trial led by Weill Cornell Medicine and other Beyond the Headlines: FDA Warning

Semaglutide-Associated Hyposalivation: A Report of Case Series. Medicine , vol

By multiple, we mean at least three, but many patients may have five or more (Laiteerapong N, Iveniuk J, John PM, Laumann EO, Huang ES

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

GLP-1 medications can suppress appetite and worsen gastrointestinal symptoms, increasing the risk of malnutrition or sarcopenia issues already prevalent in older CKD patients

Next, in our isolated heart model of IRI (Figure 8B), we show that a 20-minute perfusion with GLP-1 (6 nM) improved functional LVDP recovery following IRI as compared with buffer-treated controls (52.4% 2.7% vs